Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (28857)	7/18/2002 12:16:46 PM
From: arnold silver	Respond to of 29382

ken, one of my dogs is moving, and big volume,about 10k shares now. LOL here is some news, Lung Cancer Patient Reaches Five-Year Survival Mark After Treatment With Introgen's ADVEXIN(R) Gene Drug Therapy AUSTIN, Texas, July 2 /PRNewswire-FirstCall/ -- A late-stage lung cancer patient treated with ADVEXIN(R) adenoviral p53 gene drug therapy has survived for sixty-three months, Introgen Therapeutics Inc. (Nasdaq:INGN) announced today. Typically, the midpoint of known survival time is six months for end- stage lung cancer patients who, like her, have failed conventional treatments such as surgery or chemotherapy. The patient experienced no significant side effects during treatment. She received ADVEXIN in 1997 as part of a phase 1 trial at The University of Texas M. D. Anderson Cancer Center in Houston after being diagnosed with metastatic non-small cell lung cancer. The patient's tumor could not be surgically removed because the cancer had spread within the lungs, and multiple courses of chemotherapy had failed to stop the tumor's growth. "The fifth year anniversary of this lung cancer patient's survival suggests the exciting potential of ADVEXIN as a cancer drug," said James A. Merritt, M.D., Introgen's chief medical officer. "Introgen maintains a vigorous clinical trials program to evaluate ADVEXIN as a drug treatment for a range of cancers, including two phase 3 studies designed to obtain marketing approval from the FDA and other regulatory agencies." ADVEXIN is a drug whose active ingredient is the p53 tumor suppressor gene, which kills cancer cells or stops tumor growth via an adenoviral delivery system without harming normal cells. When ADVEXIN is administered to patients, large quantities of the non-toxic p53 gene overwhelm cancer cells and then are quickly cleared from the body. ADVEXIN is extremely well tolerated, with only minimal side effects demonstrated in 20 clinical studies involving eight different cancer types. The two phase 3 studies designed to obtain marketing approval -- currently enrolling patients in North America, Western and Eastern Europe -- are evaluating ADVEXIN in the treatment of recurrent and refractory head and neck cancer. Introgen also recently began enrolling breast cancer patients in a new phase 2 clinical study at The University of Texas M. D. Anderson Cancer Center that will evaluate ADVEXIN as a treatment for women with advanced breast cancer in combination with two chemotherapy drugs. Additionally, Introgen has completed multiple phase 2 studies that have demonstrated ADVEXIN's safety and clinical activity, and the ongoing clinical development program includes 20 clinical studies testing ADVEXIN alone and in combination with other treatments for a variety of cancers including lung, head and neck, breast, prostate, brain, bladder and other cancers. Sorry I couldn't get the link Arnie